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Trial DesignRAte Control Efficacy in permanent atrial fibrillation: a
comparison between lenient versus strict rate control
in patients with and without heart failure.
Background, aims, and design of RACE II
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Elisabeth M. TenVergert, PhD,k and Maarten P. Van Den Berg, MDa Amsterdam, Arnhem, Alkmaar, Breda, and
Groningen, The NetherlandsBackground Recent studies demonstrated that rate control is an acceptable alternative for rhythm control in
patients with persistent atrial fibrillation (AF). However, optimal heart rate during AF is still unknown.
Objective To show that in patients with permanent AF, lenient rate control is not inferior to strict rate control in
terms of cardiovascular mortality, morbidity, neurohormonal activation, New York Heart Association class for heart
failure, left ventricular function, left atrial size, quality of life, and costs.
Methods The RACE II study is a prospective multicenter trial in The Netherlands that will randomize 500 patients
with permanent AF (V12 months) to strict or lenient rate control. Strict rate control is defined as a mean resting heart rate
b80 beats per minute (bpm) and heart rate during minor exercise b110 bpm. After reaching the target, a 24-hour
Holter monitoring will be performed. If necessary, drug dose reduction and/or pacemaker implantation will be
performed. Lenient rate control is defined as a resting heart rate b110 bpm. Patients will be seen after 1, 2, and 3 months
(for titration of rate control drugs) and yearly thereafter. We anticipate a 25% 2.5-year cardiovascular morbidity and
mortality in both groups.
Results Enrollment started in January 2005 in 29 centers in The Netherlands and is expected to be concluded in June
2006. Follow-up will be at least 2 years with a maximum of 3 years.
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Rate control may be adopted as first choice therapy in
atrial fibrillation
Permanent atrial fibrillation (AF) is not a benign
disease.1 It may cause symptoms and is associated with
thromboembolic complications. Some patients with
longer-lasting AF may develop left ventricular dysfunc-
tion, even those without underlying heart disease
(tachycardiomyopathy). The AFFIRM, RACE, PIAF, and
STAF studies and others (HOT CAFE´) established that
morbidity and mortality was comparable between rate
and rhythm control therapy.2-6 As a result, rate control
may now be adopted as first choice therapy in a variety
of patients, especially those with minor symptoms and a
high chance on AF recurrences or adverse effects related
to antiarrhythmic drugs. However, the optimal level of
heart rate control with respect to morbidity and
mortality remains unknown.
American Heart Journal
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The question remains whether strict rate control is
associated with an improved prognosis compared with a
more lenient approach.7 Intuitively, strict rate control is
associated with fewer symptoms, better quality of life
(QoL), a lower incidence of heart failure, and a better
survival. Strict rate control with higher drug doses, on
the other hand, could lead to drug-related adverse
effects, causing symptomatic bradycardia, leading to
falls, syncope, trauma, and preventable pacemaker
implantation. Furthermore, strict rate control does not
necessarily lead to fewer symptoms because symptoms
may be due to the underlying cardiovascular disease
rather than the heart rate. Therefore, the balance
between benefit and harm in terms of the combined end
point of morbidity, mortality, QoL, and costs remains
unknown. In AFFIRM, in accordance with the American
College of Cardiology (ACC)/American Heart Association
(AHA)/European Society Cardiology (ESC) guidelines,1 a
strict rate control approach was applied that includes a
resting heart rate b80 beats per minute (bpm) and either
a 6-minute walk test heart rate V110 bpm or a mean
heart rate on a 24-hour Holter recording V100 bpm, in
combination with a maximum heart rate V110% of
predicted maximum heart rate. It was demonstrated that
this (strict) rate control approach could be successfully
achieved in two thirds of the patients and that, in line
with previous data, h-blockers were commonly used to
accomplish this goal.8 Serious adverse effects were
uncommon. However, strict rate control was difficult to
achieve. To obtain adequate rate control, atrioventricu-
lar node ablation and pacemaker implantation were
performed in 108 (5.3%) of the 2027 patients and an
additional 147 (7.3%) patients had a pacemaker
implanted for symptomatic bradycardia due to the rate
control medication. In a subanalysis of AFFIRM data,
higher resting heart rates were not associated with a
worse outcome.9 In contrast, in the RACE study, a more
lenient rate control approach was followed (resting
heart rate b100 bpm).3 In that study, 46% of the patients
were treated with a h-blocker. Severe drug adverse
effects were also rare (0.8%). In contrast to AFFIRM,
however, a pacemaker was implanted in only 3 (1.2%) of
the 256 patients (all after atrioventricular node ablation).
The data of the post hoc analysis comparing patients in
RACE versus patients in AFFIRM randomized to rate
control suggest that the stringency of rate control does
not influence mortality and cardiovascular morbidity.
Stringent rate control, as performed in AFFIRM, was
associated with similar rates of a composite end point of
major clinical events and with similar overall survival
rates but with more pacemaker implantations.10 In a
pooled analysis of both study groups, however, we
observed a significant increased probability of a com-
posite event in the highest heart rate group (ie, heart
rate above RACE criteria, which means a resting heartrate N100 bpm) on outcome.10 However, this non-
randomized analysis is plagued by a number of meth-
odology issues. In the case of pacemaker implantations,
it cannot be determined how much of the association
was due to stringent heart rate control and how much
was due to continental differences in the threshold for
pacemaker implantation. Furthermore, the lack of
randomization means there were inherent baseline
differences in the two studies. In another post hoc
analysis of patients with AF in the setting of advanced
heart failure, we observed that higher heart rates at
baseline were not associated with a worse survival.11 In
contrast to the latter findings, Khand et al12 observed
that in patients with an impaired left ventricular
function and AF, a more strict rate control approach may
be beneficial. They randomized patients with heart
failure (left ventricular ejection fraction averaging 24%)
and AF to carvedilol plus digoxin or to digoxin alone.
After a follow-up of 4 months, heart rate was signifi-
cantly lower in the patients treated with the combina-
tion of drugs, compared with the patients who were
treated with digoxin alone (65 F 15 vs 75 F 11, P b
.0001). Compared with placebo, the addition of carve-
dilol to digoxin significantly improved left ventricular
ejection fraction (24% F 7% to 31% F 10%, P b .05).
Whether this observation is due to heart rate control
itself or a salutary effect of h-blockade in patients with
congestive heart failure cannot be determined. Further-
more, whether such more stringent heart rate control
translates into a survival benefit and a reduced morbidity
remains to be seen. A strategy producing a higher
ejection fraction does not necessarily guarantee im-
proved overall morbidity and mortality, especially if the
eventual ejection fraction is still low. Uncertainty about
the role of h-blockers under these circumstances
remains because the Cardiac Insufficiency BIsoprolol
Studies (CIBIS) did not show a survival benefit with
h-blockade in the subgroup of heart failure patients who
also had AF.13
Heart failure and neurohormonal activation
Heart failure is characterized by neurohormonal acti-
vation, including activation of the sympathetic nervous
system and the renin-angiotensin system, and an increase
in natriuretic peptides (atrial and brain natriuretic
peptides [ANP and BNP]). ANP is produced mainly in the
atria and BNP mainly in the ventricles, the main stimulus
for secretion of both hormones is thought to be stretch of
the myocytes. Both ANP and BNP correlate with
hemodynamic status and carry prognostic information in
patients with heart failure. More recently, N-terminal
proBNP (NT-proBNP) has been shown to be of value, in
particular given its stable plasma levels as compared with
BNP. Atrial fibrillation causes additional neurohormonal
activation, including increased ANP and BNP.14,15 How-
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anything, this phenomenon suggests ANP is less suitable
for monitoring hemodynamic status in patients with AF.
In contrast, (NT-pro)BNP, which is not produced by
atrial myocytes, would appear more suitable for moni-
toring hemodynamic status in patients with AF. The aim
of the neurohormonal substudy in the present protocol is
to buttress the hypothesis that lenient rate control is not
inferior to strict rate control.Flow chart of lenient and strict rate control.Study design and methods
The RACE II study (Figure 1) is being conducted in
29 centers in The Netherlands. The institutional review
board of each institution approved the study, and all
patients gave written informed consent. Recruitment
began in January 2005, randomization is expected to be
concluded in June 2006, and follow-up will be termi-
nated in June 2008. At present, 375 patients have been
included. The trial is funded by grants from the
Netherlands Heart Foundation and the Interuniversity
Cardiology Institute, The Netherlands.
Hypothesis, patient selection, and randomization
The primary hypothesis of the RACE II study is that
lenient rate control is not inferior to strict rate control
in patients with permanent atrial fibrillation, with or
without heart failure, in terms of cardiovascular mor-
tality and morbidity, neurohormonal activation, New
York Heart Association (NYHA) class for heart failure,
left ventricular function, left atrial size, QoL, and costs.
Cardiovascular morbidity in this trial is defined as a
composite of hospitalization for left or right ventricular
heart failure, stroke, systemic emboli, bleeding, ar-
rhythmic or potential arrhythmic events, including
syncope, sustained ventricular tachycardia, cardiac
arrest, life-threatening adverse effects of rate control
drugs, pacemaker or internal cardioverter defibrillation
implantation. Stroke is defined as a disabling hemor-
rhagic, ischemic, or undetermined stroke confirmed by
a neurologist on the basis of computerized tomography
or magnetic resonance imaging and necessitating
hospitalization. Systemic emboli have to be confirmed
by a physician, typically with some type of imaging,
and require hospitalization. Bleeding is defined as a
bleeding episode where the hemoglobin value de-
creased by N2 g/L or required blood transfusion or
hospitalization or was fatal. Syncope is defined as
sudden temporary loss of consciousness associated with
a loss of postural tone with spontaneous recovery not
requiring electrical or chemical cardioversion. Sustained
ventricular tachycardia must be documented on elec-
trocardiogram (ECG) and requires hospitalization. Car-
diac arrest is defined as a circulatory arrest requiring
resuscitation and hospital admission. Life-threatening
adverse effects of rate control drugs include digitalisintoxication, drug-induced heart failure, and conduction
disturbances necessitating hospital admission. A com-
mittee of experts who are unaware of the treatment
assignments will adjudicate all possible end points. Each
component of the primary composite end point will
also be a secondary end point.
To be eligible, patients must meet all of the following
criteria: (1) a current episode of permanent AF V12
months documented on two consecutive ECGs (without
known spontaneous conversion), (2) age V80 years,
(3) mean resting heart rate N80 bpm with or without
rate control medication, and (4) oral anticoagulation
(or aspirin if no risk factors for thromboembolic
complications are present).
The exclusion criteria are as follows: (1) paroxysmal
AF, (2) known contraindications for either strict or
lenient rate control (eg, previous adverse effects on
negative chronotropic drugs), (3) unstable heart failure
defined as NYHA IV heart failure or heart failure
necessitating hospital admission b3 months before
inclusion, (4) cardiac surgery b3 months, (5) any stroke,
American Heart Journal
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defibrillator, and/or cardiac resynchronization therapy,
(7) signs of sick sinus syndrome or AV conduction
disturbances (ie, symptomatic bradycardia or asystole N3
seconds or escape rate b40 bpm in awake symptom-free
patients), (8) untreated hyperthyroidism or b3 months
euthyroidism, (9) inability to walk or bike.
Discontinuation of rate control drugs before inclusion
to meet the inclusion criteria is not allowed. Patients are
randomized in an open-label fashion to the strict or
lenient rate control arm. Randomization is accomplished
at the Trial Coordination Center by an automated
randomization accessible electronically. To randomize a
patient, the clinical site must have available the com-
pleted eligibility forms, the signed consent form, the
sequential patient number, the center number, and the
authorization code. Randomization is stratified according
to study center. Random permuted blocks are used and
the block sizes are varied randomly at the various sites.
After informed consent, patients will be randomized to
(a) strict or (b) lenient rate control therapy.
Therapy for strict rate control
Therapy for strict rate control is defined as a mean
resting heart rate (12-lead resting ECG) b80 bpm and
heart rate during minor exercise (at 25% of the
maximal achieved exercise time during bicycle exercise
test) b110 bpm. Exercise test to determine activity
heart rates will only be performed after reaching the
resting target heart rate. After achievement of the rest
and activity rate control targets as defined for this
group, a 24-hour Holter monitoring will be done to
check for bradycardia (Figure 1). If the patient remains
symptomatic due to AF after achieving rate control as
defined above, 24-hour Holter monitoring or exercise
tests may be deemed necessary by the attending
physician. These investigations may lead to adjustment
of rate control drugs or atrioventricular node ablation
and even electrical cardioversion or arrhythmia surgery
(attending physician’s choice). Nevertheless, analysis is
based on an intention-to-treat basis, although such
crossovers will be noted.
Therapy for lenient rate control
Lenient heart rate control is defined as a heart rate
b110 bpm on a 12-lead resting ECG (Figure 1). If the
patient remains symptomatic due to AF after achieving
this definition of heart rate control, Holter monitoring or
exercise tests may be deemed necessary by the attend-
ing physician. These evaluations may be followed by
adjustment of rate control drugs or atrioventricular node
ablation and even electrical cardioversion or arrhythmia
surgery (attending physician’s choice). If the heart rate
target b110 bpm cannot be achieved, Holter monitoring
or exercise tests may be deemed necessary by the
attending physician. These evaluations may be followedby atrioventricular node ablation and even electrical
cardioversion or arrhythmia surgery (attending physi-
cian’s choice). As noted above, however, primary
analysis is by intention-to-treat.
Rate control medication
Primary therapy is pharmacological using h-blockers,
calcium-channel blockers, and digoxin, alone or in
combination. It is encouraged that maximal dosages of
individual rate control drugs are instituted before
adding/switching to an alternative choice rate control
medication. Secondary pharmacological therapies in-
clude sotalol or amiodarone, but use of these drugs for
heart rate control is strongly discouraged, although not
strictly (alone or in combination with one or more of
the primary pharmacological therapies) when rate
control cannot be achieved with first choice drugs.
Pacing therapies, alone or with atrioventricular node
ablation, are utilized as indicated in the view of the
treating physician.
Follow-up and outcome events
Patients will be seen after 1, 2, and 3 months (until
adequate titration of rate control therapy is as required),
whenever study end points are detected, and after
1 and 2 years at the outpatient department in the
absence of end points (Figure 2). The last study visit
(end of study) is planned 3 years after start of the study
so individual duration of follow-up will vary between
2 and 3 years.
The primary end point is defined above. In addition
to individual components of the primary end point,
secondary end points include (a) all-cause mortality;
(b) cardiovascular hospitalizations; (c) NYHA class for
exercise tolerance, left ventricular function, and left
atrial size determined by echocardiography; (d) QoL,
using a variety of general and AF-specific instruments;
(e) neurohormonal activation, measured by NT-proBNP;
( f) hospitalization for new or worsened heart failure;
( g) hospital admission for unstable angina pectoris or
myocardial infarction; (h) renal function; and (i) costs.
Quality of life
Quality of life will be studied using the Short Form–36
health survey questionnaire, the Minnesota Living with
Heart Failure questionnaire, and the Toronto Atrial
Fibrillation Severity Scale at inclusion, after 1 and 2 years
of follow-up, and at the end of study visit.
Economic evaluation
Costs will be calculated from a societal perspective.
All relevant costs inside and outside the health care
system are taken into account. Direct medical costs,
direct nonmedical costs, and indirect nonmedical costs
are calculated. The time horizon of the economic
evaluation will be equal to that of the clinical study.
Figure 2
Follow-up. HM, Holter monitoring; RR, hypertension.
American Heart Journal
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discounted at a discount rate of 4%. In addition,
sensitivity analysis will be performed in which the
influence of the major cost categories and the discount
rate will be varied to estimate the effect on the total
costs. Data about costs of hospital stay, outpatient visits,
medication, and pacemaker implants are collected
throughout the study period using case records forms.
Information on costs not made in the hospitals, general
practitioner visits, professional and nonprofessional
help, and productivity losses is collected through self-
administered patient questionnaires. If the study results
show no significant difference regarding morbidity,
mortality, or QoL, a cost minimization analysis will be
performed to determine which treatment option is most
cost-effective, otherwise a cost-effectiveness or a cost-
utility analysis will be performed.
Neurohormones
NT-proBNP will be measured at baseline and after each
year (including the end of study visit). Three to four
samples per patient will thus be obtained. Values of
NT-proBNP will not be available for the attending
physician during the course of the study.
Pacemaker indication
According to The Netherlands guidelines, symptom-
atic bradycardia or asystole N3 seconds or an escape rate
b40 bpm in awake symptom-free patients are indications
for permanent pacing. If necessary, drug dose reduction
and/or pacemaker implantation will be performed as
needed. Pacemaker implantation is part of the primary
end point.
Electronic data collection
All data will be recorded electronically and will be
transferred to the server holding the central database
at the Trial Coordination Center, which is regularlybacked up and password protected. The electronic
case record forms are monitored at regular times by
the study monitor.
End point monitoring
All (possible) end points will be sent (by fax or mail) to
the Trial Coordination Center (University Medical Center
Groningen, Groningen, The Netherlands) as soon as they
are detected. Missing data will be gathered as expedi-
ently as possible for review by the end point adjudica-
tion committee.
Concomitant medication
Patients will be treated for their underlying heart
disease according to established guidelines, including
maximal h-blocking therapy and angiotensin-converting
enzyme inhibitors for heart failure and lipid-lowering
therapy in case of coronary artery disease.
Anticoagulation
All patients must be on oral anticoagulation at
inclusion (acenocoumarol or fenprocoumon, INR 2.5-
3.5) as directed according to guidelines. Patients without
risk factors for thromboembolic complications may be
treated with aspirin.
Statistical considerations
Sample size determination and statistical analysis
The primary aim is to show noninferiority of lenient rate
control as compared with strict rate control in terms of
the primary end point. The expected incidence of the
primary end point in both groups is 25%. Noninferiority
will be established if it is shown that the absolute
difference in the incidence of the primary end point does
not exceed 2.5% (relative difference is V10%). To achieve
a power of at least 80% with a 95% confidence limit
(1-sided test with a = 5%), 250 patients in each treatment
arm are required. Because all secondary analyses are
exploratory, no formal sample size calculations have been
done. Repeated measurements analysis will be used to
analyze changes over time. Statistical evaluation will be
performed according to the intention-to-treat principle.
Kaplan-Meier techniques will be used to describe
the occurrence of the primary end point over time.Conclusions
Rate control is now first choice therapy in many
patients with AF. However, the optimal heart rate during
AF is unknown. The ACC/AHA/ESC guidelines recom-
mend a heart rate between 60 and 80 bpm in rest and 90
and 120 bpm during moderate exercise. Although, these
recommendations are arbitrary and are not evidence
based. The results of this trial should provide informa-
tion concerning two widely applicable treatment strat-
American Heart Journal
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making will be improved regardless of outcome. If a
lenient rate control approach is not inferior, it will
facilitate therapy of AF for the patient and the physician
and probably will lower costs. If not, the therapy
proposed by the ACC/AHA/ESC guidelines will after a
long wait find their basis in the clinical evidence.
We are indebted to Janneke Bergsma-Kadijk, MSc,
of the Trial Coordination Center, University Medical
Center Groningen, for her study support.
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